Anthelmin 230 mg/20 mg film-coated tablets for cats
Anthelmin 230 mg/20 mg film-coated tablets for cats
Authorised
- Praziquantel
- Pyrantel embonate
Product identification
Medicine name:
Anthelmin 230 mg/20 mg film-coated tablets for cats
Anthelmin 230 mg - 20 mg Filmomhulde tablet
Anthelmin 230 mg - 20 mg Comprimé pelliculé
Anthelmin 230 mg - 20 mg Filmtablette
Active substance:
- Praziquantel
- Pyrantel embonate
Target species:
-
Cat
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Praziquantel20.00/milligram(s)1.00Tablet
-
Pyrantel embonate230.00/milligram(s)1.00Tablet
Pharmaceutical form:
-
Film-coated tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QP52AA51
Legal status of supply:
-
Veterinary medicinal product not subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Belgium
Package description:
- (ID7) 100 Film-coated tablet: unspecified outer container with 10 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) each with 10 Film-coated tablet, closed with Foil (aluminium)
- (ID6) 50 Film-coated tablet: unspecified outer container with 5 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) each with 10 Film-coated tablet, closed with Foil (aluminium)
- (ID5) 30 Film-coated tablet: unspecified outer container with 3 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) each with 10 Film-coated tablet, closed with Foil (aluminium)
- (ID4) 10 Film-coated tablet: unspecified outer container with 1 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) with 10 Film-coated tablet, closed with Foil (aluminium)
- (ID2) 4 Film-coated tablet: unspecified outer container with 2 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) each with 2 Film-coated tablet, closed with Foil (aluminium)
- (ID1) 2 Film-coated tablet: unspecified outer container with 1 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) with 2 Film-coated tablet, closed with Foil (aluminium)
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
- KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
- KRKA tovarna zdravil d.d. Novo mesto
- TAD Pharma GmbH
- Krka-Farma d.o.o.
- Krka-Farma d.o.o.
Responsible authority:
- Federal Agency For Medicines And Health Products
Authorisation number:
- BE-V507066
Date of authorisation status change:
Reference member state:
-
Germany
Procedure number:
- DE/V/0160/001
Concerned member states:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Czechia
-
Estonia
-
Finland
-
France
-
Hungary
-
Ireland
-
Italy
-
Latvia
-
Lithuania
-
Netherlands
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
Package Leaflet
This document does not exist in this language (English). You can find it
in another language below.
Combined File of all Documents
English (PDF)
Download Published on: 27/01/2026
Labelling
This document does not exist in this language (English). You can find it
in another language below.
2402275-paren-20191028.pdf
English (PDF)
Download Published on: 27/01/2026